雷帕鸣是哪个国家生产的

(sirolimus) is a new type of immunosuppressant developed by Wyeth Company of the United States. Clinical studies on early kidney transplant patients have shown the dual effects of sirolimus. Converting cyclosporine to sirolimus (rapamin) can result in complete regression of Kaposi's tumors in patients after kidney transplantation, while maintaining normal function of the transplanted kidney.

A 2-year randomized multi-center analysis study showed that the combination of sirolimus and cyclosporine can significantly reduce the incidence of skin cancer. After early discontinuation of cyclosporine and switching to tacrolimus treatment, the overall incidence of cancer is reduced. A single-center study of 1,008 kidney transplant patients with an average follow-up period of 5 years demonstrated that the combined use of sirolimus and corticosteroids can reduce the incidence of non-melanoma skin cancer, the most common malignant tumor after kidney transplantation. Compared with other previously reported immunosuppressant regimens, the incidence rate was reduced from 7% to 2.1%.

In the same study, when the sirolimus-based immune regimen was used, the incidence of PTLD was 3.73 times higher and the incidence of renal cell carcinoma was 3.58 times higher than the general population. These values ​​are also much lower compared with previously reported rates of rise in these two cancers with tacrolimus-based therapy (27-fold for PTLD and 8-fold for renal cell carcinoma).

As an effective mTORi agent, rapamin (sirolimus tablets) has been proven to have powerful immunosuppressive activity and excellent anti-tumor effects. Kidney transplant recipients treated with mTORi have been associated with lower rates of de novo malignancy than those treated with CNIS. In this regard, patients can purchase and use this medicine with confidence. At present, the drug has also been launched in China. Patients in need can either go to domestic hospitals or pharmacies to purchase it, or contact domestic professional overseas medical service organizations (such as Medical Companion Travel) to obtain overseas more cost-effective sirolimus.

Recommended hot articles: /newsDetail/72875.html